When to use inj amikacin

Reading File

Finding Sources

Searching the Web

amikacin injection indications clinical uses dosage

Finding Sources

Reading File

I now have comprehensive information from multiple authoritative sources. Here is a complete answer:

Injection Amikacin - When to Use

Class & Mechanism

Amikacin is a semisynthetic aminoglycoside antibiotic (derived from kanamycin). It works by:

Binding the 30S ribosomal subunit and causing misreading of mRNA
Concentration-dependent bactericidal killing (higher peak = greater kill rate)
Significant post-antibiotic effect - antibacterial activity persists even after serum levels fall below MIC

Spectrum of Activity

Organism	Susceptibility to Amikacin
E. coli	~99%
Enterobacter spp.	~100%
Pseudomonas aeruginosa	~98%
Serratia spp.	~99%
Klebsiella spp.	~88%
Acinetobacter baumannii	~58%

Key advantage over gentamicin/tobramycin: Amikacin is resistant to most aminoglycoside-modifying enzymes, so gram-negative bacteria that are gentamicin-resistant are often still susceptible to amikacin. This makes it the preferred aminoglycoside for multi-drug-resistant organisms.

Does NOT cover: Anaerobes, Stenotrophomonas maltophilia, Burkholderia cepacia.

Clinical Indications

1. Serious Gram-Negative Infections (Primary Use)

Septicemia / bacteremia - especially gram-negative bacteremia
Hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia (VAP) - particularly when Pseudomonas or resistant gram-negatives are involved
Intra-abdominal infections (peritonitis, post-operative infections) - usually in combination with metronidazole or a beta-lactam
Urinary tract infections - complicated UTIs and recurrent UTIs not susceptible to other antibiotics; uncomplicated UTI dose: 250 mg IV/IM twice daily
Skin & soft tissue infections - including burns and wound infections
Bone & joint infections (osteomyelitis caused by gram-negatives)

2. CNS Infections

Meningitis from gram-negative rods - e.g., after penetrating head trauma (S. aureus, gram-negative rods); combined with vancomycin + cefepime/meropenem
Intraventricular/intrathecal amikacin for refractory gram-negative meningitis when IV levels are subtherapeutic in CSF

3. Neonatal Sepsis

One of the standard agents for early and late-onset neonatal sepsis (often combined with ampicillin or a beta-lactam)

4. Mycobacterial Infections

Tuberculosis (MDR-TB / XDR-TB) - second-line agent used in combination regimens
Nontuberculous mycobacteria (NTM) - active against M. avium complex (MAC) and M. abscessus; may substitute streptomycin in M. xenopi regimens

5. Multidrug-Resistant (MDR) Gram-Negatives

When gentamicin/tobramycin resistance is documented, amikacin is the aminoglycoside of choice
Active against many ESBL-producing and some carbapenem-resistant Enterobacterales (CRE) when other agents are exhausted

6. Synergistic Combinations

Combined with beta-lactams or vancomycin against:
- P. aeruginosa infections (synergistic combination standard of care)
- Gram-positive endocarditis (gentamicin preferred, but amikacin used if resistant)
- Enterococcal infections (enhances cell wall-active agents)

Dosage

Patient	Dose
Adults (general)	15 mg/kg/day IV/IM in 2-3 divided doses (7.5 mg/kg q12h or 5 mg/kg q8h); max 1.5 g/day
Once-daily (extended interval, preferred)	15 mg/kg IV once daily
Uncomplicated UTI	250 mg IV/IM q12h
Duration	7-10 days typically; adjust based on response

Extended-interval (once-daily) dosing is now preferred for most indications and patient populations - it is at least equally efficacious and potentially less toxic than divided dosing, due to the concentration-dependent killing and post-antibiotic effect.

Monitoring (Therapeutic Drug Monitoring)

Peak (30-90 min after infusion): target 20-35 mcg/mL; avoid >35 mcg/mL
Trough (just before next dose): keep <10 mcg/mL to reduce nephrotoxicity
Renal function (BUN, creatinine) monitored throughout therapy

Important Adverse Effects

Nephrotoxicity - usually reversible; risk increases with duration and co-use of other nephrotoxic drugs (NSAIDs, vancomycin, contrast)
Ototoxicity - can be irreversible; affects both auditory (hearing loss) and vestibular function (via 8th CN)
Dose adjustment mandatory in renal impairment

Contraindications / Cautions

Pre-existing renal impairment (use with dose adjustment only)
Pregnancy (late pregnancy - accumulates in fetal kidneys; aminoglycosides are ototoxic to the fetus)
Caution with concurrent neuromuscular blocking agents, anesthetics, and other nephrotoxic drugs

In summary, inject amikacin when you need bactericidal gram-negative coverage for serious infections, especially in hospital/ICU settings, when resistance to other aminoglycosides is likely, or when treating MDR organisms or mycobacterial disease.

Goodman & Gilman's Pharmacological Basis of Therapeutics, 13e, p. 1189-1200
Harrison's Principles of Internal Medicine, 22e, p. 1220
Katzung's Basic & Clinical Pharmacology, 16e, p. 544

This is a shared conversation. Sign in to Orris to start your own chat.